Background: Hepatocellular carcinoma (HCC) is the most common primary hepatic tumor and one of the most common cancers worldwide. HCC is a primary malignancy of hepatocellular origin. Objectives:The aim of study is to combinate therapy of transarterial chemoembolization and percutaneousethanol injection afterward emerging metatasis caused by fine needle aspiration cytology. Subjects and method: A 50 years old male patient with hepatocellular carcinoma having a diameter of tumor more than 5 cm was treated by combination of transarterial chemoembolization and percutaneous ethanol injection from December 2000. Results & Conclusion: Results of study showed that: Transarterial chemoembolization and percutaneous ethanol injection are the two of non-surgical methods for treatment of hepatocellular carcinoma which are most commonly available in applied clinical activities at present. Up to now, the patient's life expectancy after therapy is more than 6 years that means the result of treatment is very good. However, the emerging metatasis into the anterior-right-Iower chest wall that was caused by fine needle aspiration cytology should be reviewed for further evaluating clinical experience, especially in cases with quite clear imaging features of untrasonography and significantly elevated AFP level higher than 200 ng/rnl.
Carcinoma ; Hepatocellular/ pathology ; therapy

Humans ; Carcinoma, Hepatocellular/pathology* ; Liver Neoplasms/pathology*

Hepatocellular carcinoma (HCC) with sarcomatous features is a rare neoplasm which has been found in only 1.8% of surgically resected HCC and has a higher incidence of metastasis than usual HCC. We recently experienced a case of sarcomatoid HCC removed from a 49-year-old man. A surgically resected liver revealed a well-defined grayish-white solid firm mass showing extensive central necrosis and infiltrative growth margin. Microscopically, the entire tumor was composed of pleomorphic spindle cells with prominent nucleoli and frequent mitosis. It showed a sinusoidal infiltrative growth pattern at the tumor-nontumor boundary. The tumor cells reacted positively with AE3 (high molecular cytokeratin) and Vimentin and reacted negatively with AE1 (low molecular cytokeratin), cytokeratin19, carcinoembryonic antigen, alpha-fetoprotein, Factor VIII, CD31 and CD68. The spindle-shaped tumor cells were considered to originate from hepatocyte rather than from bile duct epithelium or mesenchymal elements.
Carcinoma/pathology* ; Carcinoma/pathology* ; Carcinoma, Hepatocellular/pathology* ; Case Report ; Human ; Liver Neoplasms/pathology* ; Male ; Middle Age

Hepatoid carcinoma is a primary extrahepatic neoplasm exhibiting features of hepatocellular carcinoma (HCC) in terms of morphology, immunohistochemistry, and behavior. In many cases, tumor cytoplasm is positive for alpha- fetoprotein (alpha-FP) with elevated serum alpha-FP level. Because not all hepatoid carcinomas are associated with alpha- FP overproduction, diagnosis should be made essentially by histological features of the tumor. We present a case of hepatoid carcinoma of the pancreas in a 21-year-old male patient. Abdominal computed tomography and magnetic resonance imaging revealed an inhomogeneously enhanced pancreatic head mass. Serum alpha-FP level was markedly elevated. He underwent pylorus-preserving Whipple's operation. The tumor showed hepatoid and neuroendocrine components simultaneously. The histopathological diagnosis was hepatoid carcinoma associated with neuroendocrine tumor of the pancreas. Seven months after the surgery, the patient is healthy without evidence of recurrence. To date, only 7 cases of hepatoid carcinoma of the pancreas have been reported in the literature, and this is the first case report in Korea.
Adult ; Carcinoma, Hepatocellular/pathology ; Humans ; Male ; Pancreatic Neoplasms/*diagnosis/pathology

No abstract available.
Carcinoma, Hepatocellular/*pathology ; Human ; Liver Neoplasms/*pathology ; Male ; Middle Aged

No abstract availble
Carcinoma, Hepatocellular/*pathology ; Humans ; Liver Neoplasms/*pathology ; Neoplasm Staging ; Prognosis

In recent years, growing number of literatures have supported the concept that large nodules usually found in cirrhotic livers represent premalignant lesions in the setting of chronic liver disease. With the use of advanced imaging techniques, nodules suspicious for malignancy have often been identified and resected. While some resected lesions were found to be small hepatocellular carcinomas (HCCs), others were not. Some of these non-malignant nodules were devoid of atypia, some had architectural or cytological atypia insufficient for a diagnosis of HCC though they are suggestive of a premalignant state, while others contained microscopic subnodules of HCC. In follow-up studies and series of explants from liver transplant centers, the occasional finding of microscopic foci of HCC in the nodules was confirmed and significant associations with HCC elsewhere in the same liver were established. Such findings suggested that these nodular lesions, which are referred as "dysplastic nodules" (or adenomatous hyerplasia), are probably a frequent pathway in human hepatocarcinogenesis. We discuss the pathological characteristics of dysplastic nodules and small HCCs.
Carcinoma, Hepatocellular/*pathology ; English Abstract ; Humans ; Liver Neoplasms/*pathology

Carcinoma, Hepatocellular ; pathology ; Drug Resistance, Multiple ; Humans ; Liver Neoplasms ; pathology

The tumor immune microenvironment (TIME) plays crucial roles in the growth, progression, and therapeutic response of hepatocellular carcinoma(HCC) which is a prototypical inflammation-associated cancer. The efficacy of immunotherapy largely depends on the TIME. Targeting the immune microenvironment is an attractive strategy for the treatment of HCC. This review provides the characteristics of immune microenvironment of HCC,therapeutic approaches based on immune microenvironment,and information on the immune microenvironment underlying the response or resistance of HCC to immunotherapies.
Humans ; Carcinoma, Hepatocellular/pathology* ; Liver Neoplasms/pathology* ; Tumor Microenvironment ; Immunotherapy

With the development of modern liver surgical techniques and the progress of perioperative management,the survival rate after resection of hepatocellular carcinoma has been greatly improved,but the high recurrence and metastasis rate still limits the long-term survival after surgery. Preoperative neoadjuvant therapy has been confirmed to significantly reduce the postoperative recurrence rate and prolong survival in other types of cancer,but there has been a lack of effective systemic therapy for hepatocellular carcinoma for a long time,so the efficacy and regimen of neoadjuvant therapy for hepatocellular carcinoma are still controversial. PD-1/PD-L1 monoclonal antibody combined with anti-angiogenic targeted drugs has become a first-line regimen in systemic therapy for advanced hepatocellular carcinoma. This regimen has definite efficacy and high safety,bringing hope for neoadjuvant therapy of hepatocellular carcinoma. Recently,three clinical trials of neoadjuvant immunotherapy for hepatocellular carcinoma have been published internationally,which preliminarily suggest the efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma and lay a solid foundation for carrying out larger sample clinical studies in the future.
Humans ; Carcinoma, Hepatocellular/pathology* ; Neoadjuvant Therapy ; Liver Neoplasms/pathology* ; Immunotherapy